

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2010

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION
(Translation of registrant's name into English)

48th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.

Other Events

On September 15, 2010, China Cord Blood Corporation (the “Company”) issued a press release announcing that its subsidiary Beijing Jiachenhong Biological Technologies Co., Ltd. had entered into a framework agreement regarding the formation of an entity intended to obtain a license to conduct exclusive cord blood banking operations in Zhejiang province. A copy of the press release is attached as Exhibit 99.1, and a translation of the framework agreement is attached as Exhibit 99.2.

On September 15, 2010, the Company issued a second press release announcing that its Board of Directors had approved a share repurchase program in the aggregate amount of \$15 million for the period commencing with the announcement and continuing until September 14, 2011. A copy of the press release is attached as Exhibit 99.3.

Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated September 15, 2010, regarding Framework Agreement.
99.2	English Translation of Framework Agreement, dated September 15, 2010
99.3	Press Release, dated September 15, 2010, regarding Share Repurchase Program.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHINA CORD BLOOD CORPORATION

By: /s/ Albert Chen

Name: Albert Chen

Title: Chief Financial Officer

Dated: September 15, 2010

China Cord Blood Corporation Announces Framework Agreement Regarding Fourth License – Zhejiang Province

Enters New Province to Further Execute Geographic Expansion

HONG KONG, China, September 15, 2010 - - **China Cord Blood Corporation** (“CCBC” or “the Company”) (NYSE: CO), the first and largest cord blood bank operator in China today announced that the Company has entered into a framework agreement to form an indirect non-wholly owned subsidiary with the Zhejiang Provincial Blood Center. Through the new entity, the Company will obtain its fourth exclusive license to conduct private and public cord blood stem cell storage services in China. The new entity will enable CCBC to operate exclusively in the Zhejiang province, a new and previously untapped geographic area in China.

According to the framework agreement, CCBC will own 90% of the new entity via a cash investment of RMB45 million (\$6.6 million). The Company’s internal cash reserves will fund the investment. The remaining 10% will be satisfied by Zhejiang Provincial Blood Center and secured through the contribution of physical assets. The registration and regulatory application for the new entity will commence immediately.

Under the “One license per region policy” in China, only one cord blood bank license is granted in each province or municipality. The exclusive Zhejiang cord blood bank license represents the seventh license issued in China and it will be the first license issued since early 2008. In China, CCBC is the only cord blood operator with multiple licenses and of the seven licenses issued, CCBC owns the licenses to operate exclusively in Beijing municipality and in Guangdong province. The Company also has a 19.9% minority equity interest in the exclusive operator in Shandong province, and now will form the subsidiary to operate exclusively in the Zhejiang province.

“Our entry into Zhejiang province marks a major expansion in our nationwide coverage,” said Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation. “Zhejiang province is one of the most affluent regions in China with over 520,000 new births per annum, and we expect to capitalize on this huge addressable market. Our ability to obtain the Zhejiang license speaks to our industry reputation and our leadership position. Importantly, this is an accretive transaction for us and it involves no acquisition premium as well.”

Ms. Zheng continued, “We are confident that we can replicate our success in Guangdong and Beijing in the exciting Zhejiang marketplace. Upon completion, we will immediately start deploying our management resources in an effort to facilitate the establishment of advance infrastructure, early market education, and arouse public awareness of the benefits of umbilical cord blood storage.”

“In the meantime, we will continue to improve operational efficiency and penetration within our local markets, and to explore and evaluate new business opportunities, so that we can reward our shareholders by delivering high and sustainable growth, as well as becoming the most dominant operator in the Asia Pacific region.”

Audio Webcast

The Company will hold a teleconference at 9:30 p.m. ET on Wednesday, September 15, 2010 to give a brief overview of the Company’s recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the following link: <http://investor.chinacordbloodcorp.com/playerlink.zhtml?c=206671&s=wm&e=3368686>. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-866-586-2813 for US callers or +852-800-965808 for Hong Kong callers, access code: 11204994.



中國臍帶血庫企業集團

China Cord Blood Corporation

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses available as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at <http://www.chinacordbloodcorp.com>.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, LLC
In New York: Ashley M. Ammon or Christine Duan: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6599-7968

Framework Agreement
on the Establishment of Zhejiang Provincial Cord Blood Hematopoietic Stem Cells Bank

between Zhejiang Provincial Blood Center
and
Beijing Cord Blood Hematopoietic Stem Cells Bank
Beijing Jiachenhong Biological Technologies Co., Ltd.

September 2010

The Agreement has been hereby executed by and between the parties on 15, September 2010 (hereinafter referred to as “date of execution”) in Hangzhou, Zhejiang Province, China.

Subject:

Based on their mutual understanding and collaboration over years, **Zhejiang Provincial Blood Center** and **Beijing Cord Blood Hematopoietic Stem Cells Bank** as well as its owner **Beijing Jiachenhong Biological Technologies Co., Ltd.**, through cordial negotiations, have decided to bring their respective strengths into full play by establishing Zhejiang Lukou Biotechnology Co., Ltd. (hereinafter referred to as “Zhejiang Company”), and by jointly investing in, constructing and operating Zhejiang Provincial Cord Blood Hematopoietic Stem Cells Bank. As such, the collaborating parties hereby execute the Agreement as an attestation of their undertakings.

Purpose: To develop the cord blood hematopoietic stem cells banking in the Zhejiang region, to accelerate the popularization of clinical applications of cord blood, and to provide the local public with professional, high quality cryopreservation services for cord blood hematopoietic stem cells so as to benefit more patients.

Total investment: RMB100 million.

Registered capital: RMB50 million.

Whereas:

- Zhejiang Provincial Blood Center** (hereinafter referred to as “the Provincial Blood Center”) is a health institution set up with approval by Zhejiang Provincial Government and directly subordinate to the Provincial Health Department. It is at a domestically advanced level in terms of blood collection, storage, quality of clinical blood transfusion, technology to safeguard the safety of the blood clinically used by the public and standardized systems; the cord blood hematopoietic stem cells bank set up thereby in accordance with approval by the Ministry of Health is also among the first in the country to conduct research in technical fields such as cord blood collection, testing, cryopreservation and recovery of cord blood hematopoietic stem cells, etc, and its current overall level is also among the more advanced in the country.
 - Beijing Cord Blood Hematopoietic Stem Cells Bank** (hereinafter referred to as “ Beijing Cord Blood Bank”) is a special blood station that was set up with approval from the Ministry of Health, in accordance with applicable laws and regulations and applicable provisions and that has received a blood station business license. It is mainly engaged in business such as collection, preparation, cryopreservation and custody, etc. of cord blood hematopoietic stem cells. **Beijing Jiachenhong Biological Technologies Co., Ltd.** (hereinafter referred to as “Jiachenhong Company”), the operator and owner of Beijing Cord Blood Bank, is a limited liability company established in accordance with the Laws of the People’s Republic of China and it wholly invests in, owns and operates Beijing Cord Blood Bank. Since its establishment, Jiachenhong Company has been dedicated to publicizing and popularizing knowledge related to hematopoietic stem cells as well as their value of application to the whole society, while at the same time investing human and financial resources in scientific research related to the storage of hematopoietic stem cells and other clinical applications. It has also continuously made public charitable donations. It does not only have substantial capital strength, but also has advanced managerial experience and is a participant in the establishment of standards for the cord blood industry in China.
-

Chapter 1 Interpretations

Clause 1 Unless otherwise indicated or covenanted in the Agreement and attachment(s), the meanings of the following concepts shall be:

- (1) The “Zhejiang Cord Blood Bank” shall mean “Zhejiang Provincial Cord Blood Hematopoietic Stem Cells Bank” that is the cooperation between Zhejiang Provincial Blood Center and Beijing Jiachenhong Biological Technologies Co., Ltd. and that has added authorized custody services. It operates on the model of “coexistence of public and private bank and subsidizing public bank by private bank” and is further expanding development and operations through Zhejiang Company. Its establishment and acceptance inspection have been approved by the Ministry of Health.
 - (2) “The Provincial Blood Center” shall mean Zhejiang Provincial Blood Center.
 - (3) “Beijing Cord Blood Bank” shall mean Beijing Cord Blood Hematopoietic Stem Cells Bank.
 - (4) “Jiachenhong Company” shall mean Beijing Jiachenhong Biological Technologies Co., Ltd., the operator and owner of Beijing Cord Blood Hematopoietic Stem Cells Bank.
 - (5) “Cord blood” shall mean placental and cord blood that is not related to the blood capacities and blood circulations of pregnant women and newborn babies and that exists at the remote end of the umbilical cords of newborn babies after the umbilical cords have been cut off.
 - (6) “Zhejiang Company” shall mean Zhejiang Lukou Biotechnology Co., Ltd, the entity which jointly formed by both parties,. The purpose for setting up the company is to better implement the course of the Ministry of Health to “allow depositors to choose the storage method for cord blood,” explore and practice the operating model of “coexistence of public and private banks and subsidizing public bank by private bank” of cord blood banks of our country and to operate Zhejiang Cord Blood Bank by using the private bank to subsidize the public bank, so as to promote the joint development of the public bank and private bank and to benefit the public.
-

Chapter 2 Framework and Basic Principles of Cooperation

Section 1 Basic Framework for Mutual Cooperation

Clause 2 Both parties agree and acknowledge that on the principles of facilitating the healthy and steady operations and development of Zhejiang Cord Blood Bank, they have reached the following agreements with regard to the development and future operations of Zhejiang Cord Blood Bank:

- (1) Jiachenhong Company and the Provincial Blood Center will jointly set up “Zhejiang Company,” which has qualifications as an independent legal entity, for a total investment of RMB100 million.
 - (2) The first installment of registered capital of “Zhejiang Company” is RMB50 million. The equity structure is a monetary capital contribution by Jiachenhong Company with an equity percentage of 90%; the Provincial Blood Center will make a non-monetary capital contribution with technologies and equipment, etc., with an equity percentage of 10%.
 - (3) Upon the establishment of “Zhejiang Company,” Zhejiang Company will, as the operator and capital investor of Zhejiang Cord Blood Bank, complete the application of business permission for Zhejiang Cord Blood Bank jointly with the Provincial Blood Center and obtain the blood station business license issued by competent authorities in charge.
 - (4) “Zhejiang Company” will set up a board of directors consisting of three members, of whom one shall be from the Provincial Blood Center; one from Beijing Cord Blood Bank and one from Jiachenhong Company.
 - (5) The operating model of Zhejiang Cord Blood Bank shall be:
 1. In the name of “Zhejiang Provincial Cord Blood Hematopoietic Stem Cells Bank,” Zhejiang Cord Blood Bank shall engage in the collection, preparation, cryopreservation of cord blood, and provide cord blood hematopoietic stem cells to medical institutions and scientific and research institutions;
 2. The professional technicians of the Provincial Blood Center shall provide guidance and management of the business process and quality control of the clinical collection, preparation, cryopreservation and testing of cord blood; “Zhejiang Company” shall hire professional technicians who meet the requirements for the appropriate duty posts to engage in technical works related to steps such as the preparation, cryopreservation and testing of cord blood hematopoietic stem cells;
-

3. "Zhejiang Company" shall be responsible for resolving needs for the place of operations and buildings for business of the Zhejiang Cord Blood Bank; and for acquiring all fixed assets including facilities and equipments;
4. "Zhejiang Company" shall bear the cost of the development and operations of the Zhejiang Cord Blood Bank and bear the entire cost of operations of the Zhejiang Cord Blood Bank;
5. To maintain the normal operations of the Zhejiang Cord Blood Bank and promote the development of the cord blood health business conducted by the Zhejiang Cord Blood Bank, the Zhejiang Cord Blood Bank may engage in authorized custody services;
6. The Provincial Blood Center shall establish and issue systems and standards related to the professional and technical management of the Zhejiang Cord Blood Bank, deliver the industry regulations and business guidance rules promulgated by competent authorities in charge of the industry and correspondence documents related to the operations of the Zhejiang Cord Blood Bank, etc.

Section 2 The Rights and Obligations of Both Parties

Clause 3 Both parties agree to respectively provide cooperative conditions, perform cooperative obligations and to be entitled to the rights to cooperation and undertake confidentiality responsibilities in accordance with the covenants of the Agreement. Both parties shall execute a separate confidentiality agreement with respect to confidentiality responsibilities.

Clause 4 The basic rights and obligations of the Provincial Blood Center:

- (1) Provide the Zhejiang Cord Blood Bank with technical guidance and business management as well as relevant technicians for the collection, preparation, quality control, cryopreservation and recovery of cord blood.
 - (2) Not undertake of the operational risks of the Zhejiang Cord Blood Bank.
 - (3) Be responsible for constructing properties available for the operations of the Zhejiang Cord Blood Bank and Zhejiang Company and have ownership of such properties, provided that the provision of buildings for operations and office use to the Zhejiang Cord Blood Bank and Zhejiang Company in appropriate manner is guaranteed, with usable area not less than 1,500 square meters, and the guaranteed term of use shall not be less than 20 years.
 - (4) Facilitate and provide assistance for the clinical applications of cord blood hematopoietic stem cells by the Zhejiang Cord Blood Bank.
-

- (5) Complete all procedures related to the license renewal and continued existence of the Zhejiang Cord Blood Bank, strive for approval for the Zhejiang Cord Blood Bank of the renewal of license from the competent health and administrative authorities, so as to maintain a continuously valid license and its renewal for the Zhejiang Cord Blood Bank.
- (6) Report to the competent health and administrative authorities the relevant issues on Zhejiang Cord Blood Bank.
- (7) Provide the Zhejiang Cord Blood Bank related technical services such as medical testing agents, etc., that meet industry standards for fees.
- (8) Agree to allow Zhejiang Company to operate the Zhejiang Cord Blood Bank by a method of subsidizing the public bank by the private bank and to be responsible for the operations of the public bank.
- (9) As one of the investors in the Zhejiang Company, shall have the right to invite an accounting firm, which is an independent third party, at any time to perform audit on the financial status of Zhejiang Company at its own expense.

Clause 5 Fundamental Rights and Obligations of Jiachenhong Company:

- (1) Make total capital commitment to fund the operation of Zhejiang Cord Blood Bank by contributing equity fund to “Zhejiang Company”.
 - (2) Bear the operational risks of Zhejiang Cord Blood Bank through “Zhejiang Company”.
 - (3) Assist in dealing with all formalities in connection with the license renewal and continued existence of Zhejiang Cord Blood Bank.
 - (4) through “Zhejiang Company”, provide fixed assets and meet other physical conditions such as business premises, site, environment, facilities and equipments that are necessary to the operational needs of Zhejiang Cord Blood Bank.
 - (5) In order to expedite the establishment and development of Zhejiang Provincial Cord Blood Bank, Jiachenhong Company shall make payment of RMB30 million (RMB Thirty Million Only) by installments to Provincial Blood Center for the establishment of Zhejiang Cord Blood Bank. Zhejiang Provincial Blood Center shall especially construct the relevant property with usable area of not less than 1,500 square meters for the operation of Zhejiang Company and storage of cord blood with a term of not less than 20 years.
 - (6) Upon the establishment of Zhejiang Company, guarantee that, during the initial three years, the total amount of profit and technical consultant fees paid by Zhejiang Company to Provincial Blood Center is not less than RMB2 million (RMB Two Million Only) per year. Thereafter, profit would be shared in proportion to the shareholding percentage.
-

- (7) Pay the salaries and benefits of staff of Provincial Blood Center in Zhejiang Cord Blood Bank through “Zhejiang Company”.
- (8) Be responsible for the daily operation and management of Zhejiang Cord Blood Bank through “Zhejiang Company”, has the right of management of Zhejiang Cord Blood Bank for a term of not less than 20 years.
- (9) Zhejiang Company shall extend full support to the operation of public bank with Zhejiang Provincial Blood Center as the main entity. On the basis of maintaining the existing cryopreserved quantity of public bank, the quantity which is successfully collected and cryopreserved every year in the public bank shall be no less than 10% of that in the private bank. The number of new cases in public bank shall reach 10,000 in 10 years. Hence, for the cord blood hematopoietic stem cells which are successfully stored in the public bank, apart from being lawfully provided by Zhejiang Cord Blood Bank for the use in clinical transplantation, they can also be used to satisfy the needs for scientific research and charitable purposes of Provincial Blood Center.
- (10) Through Zhejiang Company, be responsible for the recruitment of professional technical personnel, who meet the requirements of the relevant posts, to engage in related technical work of different phases such as the preparation, cryopreservation, testing of cord blood hematopoietic stem cells; be responsible for the recruitment of financial staff, administrative management staff, back-up support staff to carry out the financial, administrative management and back-up support works of Zhejiang Cord Blood Bank.

Section 3 Cooperation Period

Clause 6 Both parties agree that the cooperation period of both parties under the Agreement shall be not less than 20 years commencing from the date of formal operation of Zhejiang Cord Blood Bank.

Chapter 3 Representations and Undertakings of Both Parties

Clause 7 Provincial Blood Center confirms, undertakes and warranties that during the performance of the Agreement, Provincial Blood Center shall not, by itself or jointly with any third parties, engage in cooperation in the field of cord blood and cord blood hematopoietic stem cells. All possible cooperations with third parties shall be confirmed mutually in writing by Provincial Blood Center and Jiachenhong Company and carried out in the name of Zhejiang Company.

Clause 8 Jiachenhong Company confirms, undertakes and warranties that it is a limited liability company with good standing which is lawfully established and existed according to the Law of the People's Republic of China and with lawful and normal operations. It possesses independent legal entity status and full capacity for civil conduct, has the right to conduct civil acts on its own in accordance with the Laws of the People's Republic of China, enjoys civil rights, fulfils civil obligations and takes up civil liabilities. According to the lawful, valid resolutions made by the board of directors of Jiachenhong Company pursuant to the articles of association, it has obtained all the valid approvals and authorizations required for the signing and performance of the Agreement, is entitled and capable of signing and performing the Agreement.

Chapter 4 Effect of the Agreement

Clause 9 The Agreement constitutes the stipulations binding on both parties in relation to all matters of mutual cooperation and carries the legal status and effect of a contract. Matters to be conducted pursuant to the stipulations of the Agreement, such as the establishment of Zhejiang Company, the establishment of Zhejiang Cord Blood Bank, recruitment of relevant personnel, construction and lease of relevant property and the mode of operation of Zhejiang Cord Blood Bank, shall inevitably or mandatorily involve the execution of such documents as specific contracts, articles of association and agreements. At that time, each of the two parties must abide by the principles set out in the basic framework as established under the Agreement and conduct detailed negotiations. Except where changes arise in national laws, regulations and policies, any violation of the principles as set out in the Agreement which renders the mutual cooperation impossible or actions that hinders its smooth proceeding shall be deemed in default of the Agreement. The opposite party shall have the right to terminate the Agreement. The defaulting party will be held liable for the default and shall compensate the opposite party for its economic losses.

Chapter 5 Variation and Termination of the Agreement

Clause 10 Any variation to the Agreement, as agreed upon by both parties, shall be made in writing.

Clause 11 The Agreement cannot be terminated arbitrarily. In the event of termination of the Agreement by reason of default or as agreed upon by both parties, each party shall return the documentary information which has already been provided to the other party within ten days of the termination and settle economic matters that have already occurred.

Chapter 6 Resolution of Disputes

Clause 12 Any dispute arising from the performance of the Agreement shall be resolved by both parties through cordial negotiations. Should they fail to reach an agreement, any of the two parties shall be entitled to bring an action to the People's Court of the place where "Zhejiang Company" is located.

Chapter 7 Validity of the Agreement

Clause 13 The Agreement is effective from the date of signing or affixing company chops by the authorized agent of each of the parties.

Chapter 8 Other Provisions

Clause 14 The parties hereto may conduct additional negotiations as regards matters that are not addressed herein and enter into supplementary agreements, which constitute an inseparable part of the Agreement and carry the same legal effect as the Agreement.

Clause 15 The Agreement is executed in sextuplicate originals, with each party holding three copies. Each of the copies carries the same legal effect.

(No main text below)

(This page is the signing page for the *Framework Agreement on the Establishment of Zhejiang Provincial Cord Blood Hematopoietic Stem Cells Bank*)



中國臍帶血庫企業集團

China Cord Blood Corporation

China Cord Blood Corporation Announces Mandate for Share Repurchase Program

HONG KONG, China, September 15, 2010 - - **China Cord Blood Corporation** (“CCBC” or “the Company”) (NYSE: CO), the first and largest cord blood bank operator in China, today announced that its Board of Directors has authorized a share repurchase program which will allow the Company to buy up to \$15 million worth of its ordinary shares before September 14, 2011.

The share repurchases can be made in the open market at prevailing market prices or in block trades and will be subject to restrictions relating to volume, price and timing. The timing of purchases will be determined by the Company, which will base its decisions on stock price, corporate and regulatory requirements, capital availability and other market conditions. The Company's Board of Directors will review the share repurchase program periodically and may authorize adjustment of its terms and size accordingly. The Company plans to fund repurchases made under this program from its available cash balance, as well as cash from operations. The program does not obligate the Company to acquire any particular amount of ordinary shares and may be commenced, suspended or discontinued at any time or from time to time in the Company's discretion without prior notice.

Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation, stated, “Our board of directors approved this share repurchase program to demonstrate our strong confidence in the Company's long term growth potential. We believe this program to be both an effective use of cash that will enhance shareholder value as well as a testament to our belief in the underlying strength of our Company.”

Audio Webcast

The Company will hold a teleconference at 9:30 p.m. ET on Wednesday, September 15, 2010 to give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the following link: <http://investor.chinacordbloodcorp.com/playerlink.zhtml?c=206671&s=wm&e=3368686>. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-866-586-2813 for US callers or +852-800-965808 for Hong Kong callers, access code: 11204994.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses available as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at <http://www.chinacordbloodcorp.com>.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.



中國臍帶血庫企業集團
China Cord Blood Corporation

For more information, please contact:

China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, LLC
In New York: Ashley M. Ammon or Christine Duan: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6599-7968
